The metastatic PCA tumors have been shown to be more susceptible to the LBD mutations under low androgen conditions following the application of the AR antagonists, with mutations such as F877L contributing to the conversion of enzalutamide or apalutamide into AR-activating agonists [65,66]. The gene discussed is AR; the disease is posterior cortical atrophy.